Bolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conference

Rhea-AI Summary

Bolt Biotherapeutics (Nasdaq: BOLT) announced that CEO Randall C. Schatzman, Ph.D., will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 1:00 p.m. PT. The event includes a fireside chat and opportunities for investor meetings. A live webcast will be available on Bolt's website, with archived replays accessible for 30 days post-event. Bolt is focused on developing innovative immuno-oncology agents, particularly its lead candidate BDC-1001, targeting HER2-expressing solid tumors.

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 1:00 p.m. PT (4:00 p.m. ET). Management will also be available for meetings with the investment community.

A live webcast of the presentations will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach uses immunostimulants to engage and activate myeloid cells that directly kill tumor cells. This leads to the conversion of immunologically “cold” tumors to “hot” tumors. Bolt’s lead candidate, BDC-1001, is a Boltbody ISAC comprised of a HER2-targeting biosimilar of trastuzumab conjugated to one of Bolt’s proprietary TLR7/8 agonists for the treatment of patients with HER2-expressing solid tumors. Bolt is also advancing additional Boltbody ISAC product candidates targeting CEA and PD-L1. For more information, visit https://www.boltbio.com/.

Investor Relations and Media Contacts:
Karen L. Bergman
Vice President, Communications and Investor Relations
Bolt Biotherapeutics, Inc.
650-665-9295
kbergman@boltbio.com

Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah.mccabe@sternir.com

Maggie Beller or David Schull
Russo Partners, LLC
646-942-5631
maggie.beller@russopartnersllc.com
david.schull@russopartnersllc.com

FAQ

What event will Bolt Biotherapeutics participate in on November 16, 2021?

Bolt Biotherapeutics will participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021.

What time is Bolt Biotherapeutics' presentation at the Stifel conference?

Bolt's presentation at the Stifel conference is scheduled for 1:00 p.m. PT on November 16, 2021.

Where can I watch the Bolt Biotherapeutics conference presentation?

The presentation can be viewed live on Bolt Biotherapeutics' website under the Events and Presentations page.

What is the focus of Bolt Biotherapeutics?

Bolt Biotherapeutics is focused on pioneering immuno-oncology agents that target tumors using innovative antibody conjugates.

What is the lead candidate of Bolt Biotherapeutics?

Bolt Biotherapeutics' lead candidate is BDC-1001, designed for treating HER2-expressing solid tumors.